Jochelson Maxine
From the Memorial Sloan-Kettering Cancer Center, New York, NY.
Am Soc Clin Oncol Educ Book. 2012:65-9. doi: 10.14694/EdBook_AM.2012.32.223.
Mammography is the only breast imaging examination that has been shown to reduce breast cancer mortality. Population-based sensitivity is 75% to 80%, but sensitivity in high-risk women with dense breasts is only in the range of 50%. Breast ultrasound and contrast-enhanced breast magnetic resonance imaging (MRI) have become additional standard modalities used in the diagnosis of breast cancer. In high-risk women, ultrasound is known to detect approximately four additional cancers per 1,000 women. MRI is exquisitely sensitive for the detection of breast cancer. In high-risk women, it finds an additional four to five cancers per 100 women. However, both ultrasound and MRI are also known to lead to a large number of additional benign biopsies and short-term follow-up examinations. Many new breast imaging tools have improved and are being developed to improve on our current ability to diagnose early-stage breast cancer. These can be divided into two groups. The first group is those that are advances in current techniques, which include digital breast tomosynthesis and contrast-enhanced mammography and ultrasound with elastography or microbubbles. The other group includes new breast imaging platforms such as breast computed tomography (CT) scanning and radionuclide breast imaging. These are exciting advances. However, in this era of cost and radiation containment, it is imperative to look at all of them objectively to see which will provide clinically relevant additional information.
乳腺钼靶摄影是唯一已被证明能降低乳腺癌死亡率的乳腺成像检查。基于人群的敏感度为75%至80%,但乳房致密的高危女性的敏感度仅在50%左右。乳腺超声和对比增强乳腺磁共振成像(MRI)已成为乳腺癌诊断中使用的其他标准检查方法。在高危女性中,已知超声每1000名女性可额外检测出约4例癌症。MRI对乳腺癌的检测极为敏感。在高危女性中,每100名女性可额外发现4至5例癌症。然而,超声和MRI也会导致大量额外的良性活检和短期随访检查。许多新的乳腺成像工具已经得到改进并正在研发,以提高我们目前诊断早期乳腺癌的能力。这些可分为两类。第一类是当前技术的进步,包括数字乳腺断层合成、对比增强乳腺钼靶摄影以及带有弹性成像或微泡的超声。另一类包括新的乳腺成像平台,如乳腺计算机断层扫描(CT)和放射性核素乳腺成像。这些都是令人兴奋的进展。然而,在这个成本控制和辐射防护的时代,必须客观地审视所有这些进展,以确定哪些将提供具有临床相关性的额外信息。